Hologic HOLX

Hologic, Inc. is grappling with substantial financial difficulties, primarily driven by ongoing global supply chain issues that have impaired production in its Breast Health and Diagnostics segments. Following significant acquisitions, the company has reported an 8% decline in product revenues amid rising operational costs, leading to a downward revision in its financial forecasts. Although Hologic maintains strong cash reserves of $2.29 billion, concerns are mounting regarding its ability to manage $3.07 billion in debt, particularly as it faces pressures from both recent market trends and internal revenue challenges.